美国11个医疗系统中成人患者接受基因型指导处方的机会
该研究基于美国11个IGNITE附属医疗系统2011至2016年的电子处方数据,评估成人患者暴露于CPIC level A药物的年度流行率。结果显示每年每10万患者中约15,719至17,335人暴露于至少一种level A药物,且大部分年份暴露于至少两种药物者超过7,200人,提示大量患者存在基因型指导处方的机会。
要点
- 多数年份每10万患者中超过7,200人暴露于至少两种level A药物。
- 每10万次处方事件中约4,748次可能适合基因型指导干预。
核心结论
- 美国医疗系统中相当比例成人患者暴露于CPIC level A药物,存在基因型指导处方的机会。
研究设计与样本
- 纳入≥18岁且在一个日历年内至少有一次符合处方条件的医疗就诊的成人患者,每年约720万成人患者可用于处方评估。
主要发现
- 2011年至2016年,每年每10万患者中暴露于至少一种CPIC level A药物的估计流行率从2011年的15,719(95%CI:15,658-15,781)到2016年的17,335(95%CI:17,283-17,386)。
- 多数年份每10万患者中暴露于至少两种CPIC level A药物的估计年暴露率超过7,200,2014年达到峰值7,660(95%CI:7,632-7,687)。
- 每10万次处方事件中估计有4,748次可能适合基因型指导干预。
临床怎么用
- 临床药师可参考CPIC level A基因-药物对,识别接受相关药物的成人患者并评估基因型指导处方的必要性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The value of utilizing a multigene pharmacogenetic panel to tailor pharmacotherapy is contingent on the prevalence of prescribed medications with an actionable pharmacogenetic association. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has categorized over 35 gene-drug pairs as "level A," for which there is sufficiently strong evidence to recommend that genetic information be used to guide drug prescribing. The opportunity to use genetic information to tailor pharmacotherapy among adult patients was determined by elucidating the exposure to CPIC level A drugs among 11 Implementing Genomics In Practice Network (IGNITE)-affiliated health systems across the US. Inpatient and/or outpatient electronic-prescribing data were collected between January 1, 2011 and December 31, 2016 for patients ≥ 18 years of age who had at least one medical encounter that was eligible for drug prescribing in a calendar year. A median of ~ 7.2 million adult patients was available for assessment of drug prescribing per year. From 2011 to 2016, the annual estimated prevalence of exposure to at least one CPIC level A drug prescribed to unique patients ranged between 15,719 (95% confidence interval (CI): 15,658-15,781) in 2011 to 17,335 (CI: 17,283-17,386) in 2016 per 100,000 patients. The estimated annual exposure to at least 2 drugs was above 7,200 per 100,000 patients in most years of the study, reaching an apex of 7,660 (CI: 7,632-7,687) per 100,000 patients in 2014. An estimated 4,748 per 100,000 prescribing events were potentially eligible for a genotype-guided intervention. Results from this study show that a significant portion of adults treated at medical institutions across the United States is exposed to medications for which genetic information, if available, should be used to guide prescribing.
引用
- Hicks JK, El Rouby N, Ong HH, et al. Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems. Clin Pharmacol Ther. 2021. PMID: 33428770. doi:10.1002/cpt.2161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。